Studies people at high risk of developing inflammatory bowel disease
Looks for risk factors in people at high risk of inflammatory bowel disease.
Plain-language title generated from the registry record
Registry title: SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT07011979
- Record updated
- 10 June 2025
- Original description
The goal of this observational study is to investigate characteristics of individuals at high risk for developing Inflammatory Bowel Disease (IBD) in order to identify risk factors associated with its incidence.Read full original descriptionShow less
SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease (SNU PREVENT)
The goal of this observational study is to investigate characteristics of individuals at high risk for developing Inflammatory Bowel Disease (IBD) in order to identify risk factors associated with its incidence.
The main question it aims to answer is:
What are the risk factors for developing Inflammatory Bowel Disease?
Researchers will compare groups at high risk for IBD to healthy populations and to patients already diagnosed with IBD.
Participants will
* undergo assessments of general demographic and clinical characteristics. * be monitored for symptoms using questionnaires administered at regular intervals. * have blood tests and stool examinations performed. In cases where participants undergo colonoscopy for routine clinical indications, gut biopsies will also be performed.
Inclusion: first-degree relatives of Inflammatory Bowel Disease patients; patients who are diagnosed with autoimmune diseases; patients with functional gastrointestinal disorders who are ASCA-positive.
Exclusion: Patients with symptoms such as a 10% weight loss within 3 months, abdominal pain, hematochezia, or diarrhea will undergo colonoscopy, and those diagnosed with Inflammatory Bowel Disease will be excluded; Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer.